Galera Therapeutics sells avasopasem and rucosopasem assets to Biossil Inc.

Galera Therapeutics, Inc.

Sold all dismutase mimetic assets including avasopasem (GC4419) and rucosopasem (GC4711) to Biossil Inc., a Canadian company.
Transaction closed Oct 15, 2025; Blackstone Agreement assigned to Biossil on Oct 21, 2025.
Blackstone will look solely to Biossil for all obligations under the Amended Blackstone Agreement; Galera relieved of those liabilities.
No purchase price or deal financial terms disclosed in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.